FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917242895> ?p ?o ?g. }

• W2917242895 endingPage "53" @default.
• W2917242895 startingPage "42" @default.
• W2917242895 abstract "A total of 44 bis-aryl-monocyclic polyamines, monoaryl-monocyclic polyamines and their transition metal complexes were prepared, chemically characterized, and screened in vitro against the Leishmania donovani promastigotes, axenic amastigotes and intracellular amastigotes in THP1 cells. The IC50 and/or IC90 values showed that 10 compounds were similarly active at about 2-fold less potent than known drug pentamidine against promastigotes. The most potent compound had an IC50 of 2.82 µM (compared to 2.93 µM for pentamidine). Nine compounds were 1.1–13.6-fold more potent than pentamidine against axenic amastigotes, the most potent one being about 2-fold less potent than amphotericin B. Fourteen compounds were about 2–10 fold more potent than pentamidine, the most potent one is about 2-fold less potent than amphotericin B against intracellular amastigotes in THP1 cells. The 2 most promising compounds (FeL7Cl2 and MnL7Cl2), with strong activity against both promastigotes and amastigotes and no observable toxicity against the THP1 cells are the Fe2+- and Mn2+-complexes of a dibenzyl cyclen derivative. Only 2 of the 44 compounds showed observable cytotoxicity against THP1 cells. Tetraazamacrocyclic monocyclic polyamines represent a new class of antileishmanial lead structures that warrant follow up studies." @default.
• W2917242895 created "2019-03-02" @default.
• W2917242895 creator A5001893764 @default.
• W2917242895 creator A5004134536 @default.
• W2917242895 creator A5013224698 @default.
• W2917242895 creator A5014644608 @default.
• W2917242895 creator A5017300854 @default.
• W2917242895 creator A5017888468 @default.
• W2917242895 creator A5029060285 @default.
• W2917242895 creator A5036175953 @default.
• W2917242895 creator A5040305041 @default.
• W2917242895 creator A5054603287 @default.
• W2917242895 creator A5061803958 @default.
• W2917242895 creator A5065958471 @default.
• W2917242895 creator A5076541930 @default.
• W2917242895 creator A5087656284 @default.
• W2917242895 date "2019-05-01" @default.
• W2917242895 modified "2023-10-10" @default.
• W2917242895 title "Tetraazamacrocyclic derivatives and their metal complexes as antileishmanial leads" @default.
• W2917242895 cites W1954181216 @default.
• W2917242895 cites W1963542761 @default.
• W2917242895 cites W1964004739 @default.
• W2917242895 cites W1964314803 @default.
• W2917242895 cites W1967535688 @default.
• W2917242895 cites W1969360633 @default.
• W2917242895 cites W1971536532 @default.
• W2917242895 cites W1972806542 @default.
• W2917242895 cites W1978365720 @default.
• W2917242895 cites W1984177984 @default.
• W2917242895 cites W2001207474 @default.
• W2917242895 cites W2005791926 @default.
• W2917242895 cites W2006112900 @default.
• W2917242895 cites W2007552940 @default.
• W2917242895 cites W2007684466 @default.
• W2917242895 cites W2008414120 @default.
• W2917242895 cites W2013573934 @default.
• W2917242895 cites W2014471833 @default.
• W2917242895 cites W2014596944 @default.
• W2917242895 cites W2016226797 @default.
• W2917242895 cites W2018098227 @default.
• W2917242895 cites W2034283806 @default.
• W2917242895 cites W2037429887 @default.
• W2917242895 cites W2039215936 @default.
• W2917242895 cites W2046144222 @default.
• W2917242895 cites W2053315005 @default.
• W2917242895 cites W2053699199 @default.
• W2917242895 cites W2054029713 @default.
• W2917242895 cites W2059679350 @default.
• W2917242895 cites W2064894863 @default.
• W2917242895 cites W2069996137 @default.
• W2917242895 cites W2073175688 @default.
• W2917242895 cites W2080771705 @default.
• W2917242895 cites W2084233359 @default.
• W2917242895 cites W2085886339 @default.
• W2917242895 cites W2087657927 @default.
• W2917242895 cites W2089183490 @default.
• W2917242895 cites W2093627146 @default.
• W2917242895 cites W2096322784 @default.
• W2917242895 cites W2099728302 @default.
• W2917242895 cites W2104739753 @default.
• W2917242895 cites W2105845464 @default.
• W2917242895 cites W2113056926 @default.
• W2917242895 cites W2117846173 @default.
• W2917242895 cites W2122590128 @default.
• W2917242895 cites W2124520166 @default.
• W2917242895 cites W2131595247 @default.
• W2917242895 cites W2132047956 @default.
• W2917242895 cites W2143173105 @default.
• W2917242895 cites W2144332006 @default.
• W2917242895 cites W2145336248 @default.
• W2917242895 cites W2149268709 @default.
• W2917242895 cites W2153134667 @default.
• W2917242895 cites W2156802725 @default.
• W2917242895 cites W2157739749 @default.
• W2917242895 cites W2159474176 @default.
• W2917242895 cites W2167109242 @default.
• W2917242895 cites W2170095235 @default.
• W2917242895 cites W2174912587 @default.
• W2917242895 cites W2330186838 @default.
• W2917242895 cites W2335014775 @default.
• W2917242895 cites W2342339715 @default.
• W2917242895 cites W2470921890 @default.
• W2917242895 cites W2473967854 @default.
• W2917242895 cites W2487458527 @default.
• W2917242895 cites W4250973405 @default.
• W2917242895 doi "https://doi.org/10.1016/j.poly.2019.02.027" @default.
• W2917242895 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6452907" @default.
• W2917242895 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30976133" @default.
• W2917242895 hasPublicationYear "2019" @default.
• W2917242895 type Work @default.
• W2917242895 sameAs 2917242895 @default.
• W2917242895 citedByCount "12" @default.
• W2917242895 countsByYear W29172428952019 @default.
• W2917242895 countsByYear W29172428952020 @default.
• W2917242895 countsByYear W29172428952021 @default.
• W2917242895 countsByYear W29172428952022 @default.
• W2917242895 countsByYear W29172428952023 @default.
• W2917242895 crossrefType "journal-article" @default.

• next